| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TOR1AIP2 |
| Uniprot No | Q8NFQ8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-470aa |
| 氨基酸序列 | MADSGLREPQEDSQKDLENDPSVNSQAQETTIIASNAEEAEILHSACGLSKDHQEVETEGPESADTGDKSESPDEANVGKHPKDKTEDENKQSFLDGGKGHHLPSENLGKEPLDPDPSHSPSDKVGRADAHLGSSSVALPKEASDGTGASQEPPTTDSQEAQSPGHSSAGQEGEDTLRRRLLAPEAGSHPQQTQKLEEIKENAQDTMRQINKKGFWSYGPVILVVLVVAVVASSVNSYYSSPAQQVPKNPALEAFLAQFSQLEDKFPGQSSFLWQRGRKFLQKHLNASNPTEPATIIFTAAREGRETLKCLSHHVADAYTSSQKVSPIQIDGAGRTWQDSDTVKLLVDLELSYGFENGQKAAVVHHFESFPAGSTLIFYKYCDHENAAFKDVALVLTVLLEEETLEASVGPRETEEKVRDLLWAKFTNSDTPTSFNHMDSDKLSGLWSRISHLVLPVQPVSSIEEQGCLF |
| 预测分子量 | 51,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TOR1AIP2重组蛋白的3篇参考文献摘要(基于公开信息模拟整理，建议通过学术数据库核实原文)：
1. **文献名称**：*LAP1B (TOR1AIP2) facilitates the nuclear transport of TorsinA in neuronal cells*
**作者**：Kim CE, Perez-Reyes N, et al.
**摘要**：研究通过重组TOR1AIP2(LAP1B)蛋白，揭示了其与TorsinA的相互作用机制，证明LAP1B在神经元细胞中协助TorsinA的核膜定位，对维持核膜结构及神经功能至关重要。
2. **文献名称**：*Structural insights into TOR1AIP2-mediated membrane remodeling*
**作者**：Zhao Q, Li H, et al.
**摘要**：利用重组TOR1AIP2蛋白进行体外膜结合实验，结合冷冻电镜分析，阐明其通过特定结构域诱导核膜重塑的分子机制，为相关核膜病的治疗提供理论依据。
3. **文献名称**：*Functional characterization of TOR1AIP2 mutations linked to muscular dystrophy*
**作者**：Vargas JD, Schindler AJ, et al.
**摘要**：通过表达重组突变型TOR1AIP2蛋白，发现其异常导致核膜稳定性受损及内质网应激反应激活，解释了该基因突变引发早发性肌营养不良的病理机制。
注：以上文献为示例性质，实际文献需通过PubMed、Google Scholar等平台以“TOR1AIP2 recombinant”或“LAP1B recombinant”为关键词检索获取。
**TOR1AIP2 Recombinant Protein: Background and Significance**
TOR1AIP2 (Torsin-1A-interacting protein 2), also known as LAP1 (lamina-associated polypeptide 1), is a nuclear envelope protein encoded by the *TOR1AIP2* gene located on chromosome 1q25.2. It belongs to the LAP1 family and is integral to maintaining nuclear structure and function. LAP1 interacts with TorsinA (encoded by *TOR1A*), a AAA+ ATPase implicated in nuclear membrane dynamics, endoplasmic reticulum stress response, and neuronal function. This interaction is critical for regulating TorsinA’s ATPase activity, linking LAP1 to cellular processes such as chromatin organization, mechanotransduction, and nucleocytoplasmic transport.
Mutations in *TOR1AIP2* are associated with severe human disorders, including early-onset muscular dystrophy, cardiomyopathy, and neurological abnormalities. These pathologies highlight LAP1’s role in tissue-specific nuclear envelope stability. For instance, LAP1 deficiency disrupts nuclear integrity in muscle cells, leading to progressive degeneration.
Recombinant TOR1AIP2 protein is produced using expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical properties, structure, and interactions. Its purified form enables in vitro analyses, such as binding assays with TorsinA, structural studies (e.g., X-ray crystallography or cryo-EM), and functional investigations into nuclear envelope dynamics. Researchers also utilize recombinant LAP1 to explore disease mechanisms, screen therapeutic compounds, and develop models for disorders linked to nuclear envelopathies.
The development of TOR1AIP2 recombinant protein has advanced understanding of nuclear envelope biology and its role in rare genetic diseases. Ongoing research aims to unravel tissue-specific isoforms of LAP1 and their distinct roles, potentially informing targeted therapies for neuromuscular and neurodegenerative conditions.
×
